Grabar Law Office Investigates Claims on Behalf of Shareholders of Akero Therapeutics, Inc. (AKRO)

Philadelphia, Pennsylvania--(Newsfile Corp. - May 1, 2024) - Grabar Law Office is investigating whether officers and directors of Akero Therapeutics, Inc. (NASDAQ: AKRO) breached their fiduciary duties owed to the company. If you are a shareholder and would like to learn more about the investigation and your rights, please visit https://grabarlaw.com/the-latest/akero-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085.

WHY: A recently filed securities fraud class action Complaint alleges that Akero Therapeutics, via certain of its officers and directors, made false and/or misleading statements and/or failed to disclose to the investing publics that: (i) approximately 20% of the patients enrolled in its SYMMETRY study had cryptogenic cirrhosis and did not have definitive NASH at baseline; (ii) the cryptogenic cirrhotic patients included in the SYMMETRY study did not have biopsy-proven compensated cirrhosis due to definitive NASH; (iii) the results from the cryptogenic cirrhosis patients were to be excluded from the calculation of the NASH resolution secondary endpoints; (iv) Akero had introduced a confounding factor into the SYMMETRY study's design, materially influencing the study's potential results and increasing the risks that the study would fail to meet its primary endpoint; (v) the SYMMETRY study did not align with U.S. Food & Drug Administration guidance for testing a drug in treating NASH cirrhotics because Akero had not ruled out potential causes of each patient's cirrhosis other than NASH; and (vi) consequently, Akero had materially misrepresented the nature of the SYMMETRY trial, its usefulness in supporting any new drug application, the likelihood that the SYMMETRY trial would be successful as measured by its primary endpoint, and the likelihood that EFX would become a commercial treatment for NASH cirrhotics.

WHAT YOU CAN DO: Current Akero shareholders who have held Akero shares since on or before September 13, 2022, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever.

If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/akero-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085.

Attorney Advertising Disclaimer

Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/207579